{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T23:46:56Z","timestamp":1769730416539,"version":"3.49.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T00:00:00Z","timestamp":1724976000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T00:00:00Z","timestamp":1724976000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Ministry of Health & Welfare, Republic of Korea","award":["HC21C0076"],"award-info":[{"award-number":["HC21C0076"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Rheumatol"],"DOI":"10.1186\/s41927-024-00410-w","type":"journal-article","created":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T07:02:54Z","timestamp":1725001374000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Factors associated with cause-specific discontinuation of long-term anti-tumor necrosis factor agent use in patients with ankylosing spondylitis: a retrospective cohort study"],"prefix":"10.1186","volume":"8","author":[{"given":"Bora","family":"Nam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nayeon","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bon San","family":"Koo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiyeong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tae-Hwan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,30]]},"reference":[{"issue":"9570","key":"410_CR1","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1016\/S0140-6736(07)60635-7","volume":"369","author":"J Braun","year":"2007","unstructured":"Braun J, Sieper J. Ankylosing spondylitis. Lancet. 2007;369(9570):1379\u201390.","journal-title":"Lancet"},{"issue":"1","key":"410_CR2","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/ard-2022-223296","volume":"82","author":"S Ramiro","year":"2023","unstructured":"Ramiro S, Nikiphorou E, Sepriano A, Ortolan A, Webers C, Baraliakos X, et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis. 2023;82(1):19\u201334.","journal-title":"Ann Rheum Dis"},{"key":"410_CR3","doi-asserted-by":"crossref","unstructured":"Anghel L-A, Farca\u015f AM, Oprean RN. Medication adherence and persistence in patients with autoimmune rheumatic diseases: a narrative review. Patient Prefer Adherence 2018:1151\u201366.","DOI":"10.2147\/PPA.S165101"},{"key":"410_CR4","doi-asserted-by":"publisher","first-page":"S38","DOI":"10.1002\/ddr.21192","volume":"75","author":"M Biggioggero","year":"2014","unstructured":"Biggioggero M, Favalli EG. Ten-year drug survival of anti\u2010TNF agents in the treatment of inflammatory arthritides. Drug Dev Res. 2014;75:S38\u201341.","journal-title":"Drug Dev Res"},{"issue":"6","key":"410_CR5","first-page":"857","volume":"31","author":"C Scir\u00e8","year":"2013","unstructured":"Scir\u00e8 C, Caporali R, Puttini S, Frediani P, Di Franco B, Tincani M. Drug survival of the first course of anti-TNF agents in patients with rheumatoid arthritis and seronegative spondyloarthritis: analysis from the MonitorNet database. Clin Exp Rheumatol. 2013;31(6):857\u201363.","journal-title":"Clin Exp Rheumatol"},{"key":"410_CR6","doi-asserted-by":"crossref","unstructured":"Visman I, Atiqi S, Boers M, Twisk J, Nurmohamed M. Changes in TNF inhibitor drug survival in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis over 15 years. J Rhuematol 2023.","DOI":"10.3899\/jrheum.2023-0149"},{"issue":"11","key":"410_CR7","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1136\/annrheumdis-2019-215427","volume":"78","author":"L \u00d8rnbjerg","year":"2019","unstructured":"\u00d8rnbjerg L, Brahe M, H C, Askling J, Ciurea A, Mann H, Onen F, et al. Treatment response and drug retention rates in 24 195 biologic-na\u00efve patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaboration. Ann Rheum Dis. 2019;78(11):1536\u201344.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"410_CR8","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1002\/acr.23090","volume":"69","author":"EG Favalli","year":"2017","unstructured":"Favalli EG, Selmi C, Becciolini A, Biggioggero M, Ariani A, Santilli D, et al. Eight-year retention rate of first\u2010line tumor necrosis factor inhibitors in spondyloarthritis: a multicenter retrospective analysis. Arthritis Care Res. 2017;69(6):867\u201374.","journal-title":"Arthritis Care Res"},{"issue":"4","key":"410_CR9","doi-asserted-by":"publisher","first-page":"e057850","DOI":"10.1136\/bmjopen-2021-057850","volume":"12","author":"D Benavent","year":"2022","unstructured":"Benavent D, Franco-G\u00f3mez K, Plasencia-Rodriguez C, Novella-Navarro M, Bogas P, Nieto R, et al. Achievement rate and predictive factors of the recommended therapeutical target in patients with axial spondyloarthritis who remain on biological therapy: a prospective cohort study in Spain. BMJ open. 2022;12(4):e057850.","journal-title":"BMJ open"},{"issue":"3","key":"410_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/ar3369","volume":"13","author":"S Arends","year":"2011","unstructured":"Arends S, Brouwer E, van der Veer E, Groen H, Leijsma MK, Houtman PM, et al. Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study. Arthritis Res Therapy. 2011;13(3):1\u201310.","journal-title":"Arthritis Res Therapy"},{"key":"410_CR11","doi-asserted-by":"publisher","first-page":"689609","DOI":"10.3389\/fmed.2021.689609","volume":"8","author":"H-A Kim","year":"2021","unstructured":"Kim H-A, Lee S-K, Oh S, Park EH, Park Y-B, Shin K. Comparison of retention rates between tumor necrosis factor-\u03b1 inhibitors in patients with ankylosing spondylitis: data from the Korean College of Rheumatology Biologics Registry. Front Med. 2021;8:689609.","journal-title":"Front Med"},{"issue":"11","key":"410_CR12","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1136\/ard.2009.124446","volume":"69","author":"B Glintborg","year":"2010","unstructured":"Glintborg B, \u00d8stergaard M, Krogh NS, Dreyer L, Kristensen HL, Hetland ML. Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years\u2019 surveillance in the Danish nationwide DANBIO registry. Ann Rheum Dis. 2010;69(11):2002\u20138.","journal-title":"Ann Rheum Dis"},{"key":"410_CR13","doi-asserted-by":"crossref","unstructured":"Vastesaeger N, Van Der Heijde D, Inman RD, Wang Y, Deodhar A, Hsu B et al. Predicting the outcome of ankylosing spondylitis therapy. Annals of the rheumatic diseases 2011;70(6):973\u2009\u2013\u200981.","DOI":"10.1136\/ard.2010.147744"},{"issue":"9","key":"410_CR14","first-page":"1751","volume":"32","author":"JC Davis","year":"2005","unstructured":"Davis JC, Van der Heijde DM, Dougados M, Braun J, Cush JJ, Clegg DO, et al. Baseline factors that influence ASAS 20 response in patients with ankylosing spondylitis treated with etanercept. J Rhuematol. 2005;32(9):1751\u20134.","journal-title":"J Rhuematol"},{"issue":"4","key":"410_CR15","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1093\/rheumatology\/kev392","volume":"55","author":"B Glintborg","year":"2016","unstructured":"Glintborg B, H\u00f8jgaard P, Lund Hetland M, Steen Krogh N, Kollerup G, Jensen J, et al. Impact of tobacco smoking on response to tumour necrosis factor-alpha inhibitor treatment in patients with ankylosing spondylitis: results from the Danish nationwide DANBIO registry. Rheumatology. 2016;55(4):659\u201368.","journal-title":"Rheumatology"},{"issue":"4","key":"410_CR16","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/art.1780270401","volume":"27","author":"SVD Linden","year":"1984","unstructured":"Linden SVD, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. Arthr Rhuem. 1984;27(4):361\u20138.","journal-title":"Arthr Rhuem"},{"issue":"1","key":"410_CR17","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1136\/ard.2004.020503","volume":"64","author":"M Creemers","year":"2005","unstructured":"Creemers M, Franssen M, Van\u2019t Hof M, Gribnau F, Van de Putte L, Van Riel P. Assessment of outcome in ankylosing spondylitis: an extended radiographic scoring system. Ann Rheum Dis. 2005;64(1):127\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"410_CR18","doi-asserted-by":"publisher","first-page":"e0119897","DOI":"10.1371\/journal.pone.0119897","volume":"10","author":"Q Tong","year":"2015","unstructured":"Tong Q, Cai Q, De Mooij T, Xu X, Dai S, Qu W, et al. Adverse events of anti-tumor necrosis factor \u03b1 therapy in ankylosing spondylitis. PLoS ONE. 2015;10(3):e0119897.","journal-title":"PLoS ONE"},{"issue":"1","key":"410_CR19","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1093\/rheumatology\/keq242","volume":"50","author":"JB Galloway","year":"2011","unstructured":"Galloway JB, Hyrich KL, Mercer LK, Dixon WG, Fu B, Ustianowski AP, et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology. 2011;50(1):124\u201331.","journal-title":"Rheumatology"},{"key":"410_CR20","doi-asserted-by":"crossref","unstructured":"Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Feltelius N et al. Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists. Annals of the rheumatic diseases 2007;66(10):1339-44.","DOI":"10.1136\/ard.2006.062760"},{"key":"410_CR21","unstructured":"Egeberg A, Rosen\u00f8 NAL, Aagaard D, L\u00f8rup EH, Nielsen M-L, Nymand L et al. in Seminars in Arthritis and Rheumatism. 151979 (Elsevier)."},{"key":"410_CR22","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s40259-017-0231-8","volume":"31","author":"V Strand","year":"2017","unstructured":"Strand V, Balsa A, Al-Saleh J, Barile-Fabris L, Horiuchi T, Takeuchi T, et al. Immunogenicity of biologics in chronic inflammatory diseases: a systematic review. BioDrugs. 2017;31:299\u2013316.","journal-title":"BioDrugs"},{"issue":"7","key":"410_CR23","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1136\/annrheumdis-2014-205253","volume":"74","author":"C Stolwijk","year":"2015","unstructured":"Stolwijk C, Essers I, van Tubergen A, Boonen A, Bazelier MT, De Bruin ML, et al. The epidemiology of extra-articular manifestations in ankylosing spondylitis: a population-based matched cohort study. Ann Rheum Dis. 2015;74(7):1373\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"410_CR24","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1136\/ard.2006.052092","volume":"65","author":"S Guignard","year":"2006","unstructured":"Guignard S, Gossec L, Salliot C, Ruyssen-Witrand A, Luc M, Duclos M, et al. Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study. Ann Rheum Dis. 2006;65(12):1631\u20134.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"410_CR25","doi-asserted-by":"publisher","first-page":"3248","DOI":"10.1002\/art.22918","volume":"56","author":"LL Lim","year":"2007","unstructured":"Lim LL, Fraunfelder FW, Rosenbaum JT. Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis Rheumatism: Official J Am Coll Rheumatol. 2007;56(10):3248\u201352.","journal-title":"Arthritis Rheumatism: Official J Am Coll Rheumatol"},{"issue":"1","key":"410_CR26","first-page":"9","volume":"25","author":"P Chiowchanwisawakit","year":"2019","unstructured":"Chiowchanwisawakit P, Katchamart W, Osiri M, Narongroeknawin P, Chevaisrakul P, Kitumnuaypong T, et al. Effectiveness and drug survival of anti\u2013tumor necrosis factor \u03b1 therapies in patients with spondyloarthritis: analysis from the Thai Rheumatic Disease Prior Authorization Registry. JCR: J Clin Rheumatol. 2019;25(1):9\u201315.","journal-title":"JCR: J Clin Rheumatol"},{"issue":"1","key":"410_CR27","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s00296-022-05237-7","volume":"43","author":"NE Ouardi","year":"2023","unstructured":"Ouardi NE, Maghraoui AE, Djossou H, Taoubane L, Ghassem A, Toufik H, et al. Discontinuation of biologic therapy in patients with rheumatoid arthritis and ankylosing spondylitis: analysis from multicenter cohort study. Rheumatol Int. 2023;43(1):79\u201387.","journal-title":"Rheumatol Int"},{"issue":"1","key":"410_CR28","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1002\/msc.1684","volume":"21","author":"M Pombo-Su\u00e1rez","year":"2023","unstructured":"Pombo-Su\u00e1rez M, Seoane\u2010Mato D, D\u00edaz\u2010Gonz\u00e1lez F, Cea\u2010Calvo L, S\u00e1nchez\u2010Alonso F, S\u00e1nchez\u2010Jare\u00f1o M, et al. Long\u2010term retention of golimumab treatment in clinical practice in a large cohort of patients with rheumatoid arthritis, axial spondyloarthritis and psoriatic arthritis. Musculoskelet Care. 2023;21(1):189\u201397.","journal-title":"Musculoskelet Care"},{"issue":"6","key":"410_CR29","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1136\/ard.2003.016386","volume":"63","author":"M Rudwaleit","year":"2004","unstructured":"Rudwaleit M, Listing J, Brandt J, Braun J, Sieper J. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor \u03b1 blockers in ankylosing spondylitis. Ann Rheum Dis. 2004;63(6):665\u201370.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"410_CR30","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1136\/ard.2007.073098","volume":"67","author":"M Rudwaleit","year":"2008","unstructured":"Rudwaleit M, Schwarzlose S, Hilgert E, Listing J, Braun J, Sieper J. MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis. Ann Rheum Dis. 2008;67(9):1276\u201381.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"410_CR31","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1136\/annrheumdis-2012-201766","volume":"72","author":"J Sieper","year":"2013","unstructured":"Sieper J, van der Heijde D, Dougados M, Mease PJ, Maksymowych WP, Brown MA, et al. Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). Ann Rheum Dis. 2013;72(6):815\u201322.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"410_CR32","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1002\/art.39257","volume":"67","author":"J Sieper","year":"2015","unstructured":"Sieper J, Van Der Heijde D, Dougados M, Maksymowych W, Scott B, Boice J, et al. A randomized, double-blind, placebo\u2010controlled, sixteen\u2010week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritis. Arthritis Rheumatol. 2015;67(10):2702\u201312.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"410_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12891-020-03941-8","volume":"22","author":"B Nam","year":"2021","unstructured":"Nam B, Koo BS, Lee T-H, Shin J-H, Kim J-J, Lee S, et al. Low BASDAI score alone is not a good predictor of anti-tumor necrosis factor treatment efficacy in ankylosing spondylitis: a retrospective cohort study. BMC Musculoskelet Disord. 2021;22(1):1\u20138.","journal-title":"BMC Musculoskelet Disord"},{"key":"410_CR34","doi-asserted-by":"crossref","unstructured":"Nam B, San Koo B, Choi N, Shin J-H, Lee S, Joo KB et al. The impact of smoking status on radiographic progression in patients with ankylosing spondylitis on anti-tumor necrosis factor treatment. Front Med 2022;9.","DOI":"10.3389\/fmed.2022.994797"},{"key":"410_CR35","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1007\/s11136-021-02800-w","volume":"30","author":"B Nam","year":"2021","unstructured":"Nam B, Koo BS, Nam SW, Shin J-H, Song Y, Cho S-K, et al. Gender differences in factors associated with low quality of life and depression in Korean patients with ankylosing spondylitis. Qual Life Res. 2021;30:2299\u2013310.","journal-title":"Qual Life Res"},{"issue":"6","key":"410_CR36","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1086\/313792","volume":"30","author":"TT Yoshikawa","year":"2000","unstructured":"Yoshikawa TT. Epidemiology and unique aspects of aging and infectious diseases. Clin Infect Dis. 2000;30(6):931\u20133.","journal-title":"Clin Infect Dis"},{"issue":"10","key":"410_CR37","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1136\/ard.2008.098822","volume":"69","author":"A Fouque-Aubert","year":"2010","unstructured":"Fouque-Aubert A, Jette-Paulin L, Combescure C, Basch A, Tebib J, Gossec L. Serious infections in patients with ankylosing spondylitis with and without TNF blockers: a systematic review and meta-analysis of randomised placebo-controlled trials. Ann Rheum Dis. 2010;69(10):1756\u201361.","journal-title":"Ann Rheum Dis"},{"key":"410_CR38","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1007\/s12016-017-8623-6","volume":"54","author":"L-q Hou","year":"2018","unstructured":"Hou L-q, Jiang G-x, Chen Y-f, Yang X-M, Meng L, Xue M, et al. The comparative safety of TNF inhibitors in ankylosing spondylitis\u2014a meta-analysis update of 14 randomized controlled trials. Clin Rev Allergy Immunol. 2018;54:234\u201343.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"4","key":"410_CR39","doi-asserted-by":"publisher","first-page":"3491","DOI":"10.3892\/etm.2017.5003","volume":"14","author":"Z Xu","year":"2017","unstructured":"Xu Z, Xu P, Fan W, Yang G, Wang J, Cheng Q, et al. Risk of infection in patients with spondyloarthritis and ankylosing spondylitis receiving antitumor necrosis factor therapy: a meta\u2013analysis of randomized controlled trials. Experimental Therapeutic Med. 2017;14(4):3491\u2013500.","journal-title":"Experimental Therapeutic Med"},{"key":"410_CR40","doi-asserted-by":"publisher","first-page":"1084614","DOI":"10.3389\/fphar.2023.1084614","volume":"14","author":"H Feng","year":"2023","unstructured":"Feng H, Zhao Y, Kuang W, Dai Y, Cen X, Qin F. Adverse events of tumor necrosis factor alpha inhibitors for the treatment of ankylosing spondylitis: a meta-analysis of randomized, placebo-controlled trials. Front Pharmacol. 2023;14:1084614.","journal-title":"Front Pharmacol"},{"key":"410_CR41","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1007\/s00296-016-3423-5","volume":"36","author":"J Dal\u00e9n","year":"2016","unstructured":"Dal\u00e9n J, Svedbom A, Black CM, Lyu R, Ding Q, Sajjan S, et al. Treatment persistence among patients with immune-mediated rheumatic disease newly treated with subcutaneous TNF-alpha inhibitors and costs associated with non-persistence. Rheumatol Int. 2016;36:987\u201395.","journal-title":"Rheumatol Int"}],"container-title":["BMC Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41927-024-00410-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41927-024-00410-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41927-024-00410-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T07:03:43Z","timestamp":1725001423000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcrheumatol.biomedcentral.com\/articles\/10.1186\/s41927-024-00410-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,30]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["410"],"URL":"https:\/\/doi.org\/10.1186\/s41927-024-00410-w","relation":{},"ISSN":["2520-1026"],"issn-type":[{"value":"2520-1026","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,30]]},"assertion":[{"value":"10 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed according to the guidelines of the Helsinki Declaration and was approved by the Institutional Review Board (IRB) of Hanyang University Hospital (IRB file No. HYUH 2021-10-013). Informed consent was waived because of the retrospective nature of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"39"}}